阿达木单抗血清浓度用于选择类风湿关节炎患者后续生物制剂(ADDORA-switch):一项盲法随机检测-治疗试验结果
该24周多中心三盲随机对照试验纳入因无效停用阿达木单抗的类风湿关节炎患者,比较基于谷浓度监测(TDM)与随机切换策略选择后续生物/靶向合成改善病情抗风湿药的效果。两组平均时间加权DAS28-CRP均为3.15(差值95%CI -0.46至0.47),无显著差异。作者结论为基于阿达木单抗谷浓度切换治疗并不优于随机切换,不推荐以此指导治疗选择。
要点
- 因无效停用阿达木单抗的RA患者中,TDM指导切换与随机切换的24周平均时间加权DAS28-CRP均为3.15,无显著差异。
- 两组在 flare 率、 escape 药物使用、疾病活动度和不良事件方面均无显著差异。
- 作者结论:不推荐通过检测血清药物浓度来指导此类患者的后续治疗选择。
核心结论
- 在因阿达木单抗治疗无效而停药的类风湿关节炎患者中,基于阿达木单抗谷浓度切换治疗并不比随机切换更有效,因此不推荐通过检测血清药物浓度来指导该情境下的治疗选择。
研究设计与样本
- 24周、多中心、三盲、随机对照试验,纳入因无效停用阿达木单抗(DAS28-CRP>2.9)的类风湿关节炎患者,按1:1随机分配至基于TDM的切换策略组或随机切换(对照)策略组。
主要发现
- 2020年7月至2023年11月连续纳入83例类风湿关节炎患者,其中78例启动新的b/tsDMARD(TDM组n=38,对照组n=40)。
- 两组平均时间加权DAS28-CRP均为3.15(TDM组标准差0.99,对照组标准差1.01,差值95%CI -0.46至0.47)。
- 两组在 flare 率、 escape 药物使用、疾病活动度和不良事件方面均无显著差异。
- 对照组受试者工作特征分析未发现阿达木单抗水平对TNFi或非TNFi治疗反应有预测价值。
临床怎么用
- 作者结论指出,基于阿达木单抗谷浓度切换治疗不优于随机切换,不推荐通过检测血清药物浓度来指导此类患者的后续治疗选择。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: A substantial proportion of patients with rheumatoid arthritis (RA) discontinue adalimumab due to ineffectiveness. The next treatment step can be another tumour necrosis factor inhibitor (TNFi) or a biological/targeted synthetic disease-modifying antirheumatic drug (b/tsDMARD). Therapeutic drug monitoring (TDM) of serum drug levels may help guide this choice. This study evaluated whether switching treatments based on adalimumab trough levels is more effective than random switching. METHODS: In this 24-week, multicentre, triple-blinded, randomised controlled trial, patients with RA who stopped adalimumab due to inefficacy (disease activity score based on 28 joint count and C-reactive protein [DAS28-CRP] >2.9) were enrolled. Participants were randomly assigned (1:1) to a TDM-based or random switching (control) strategy. The primary outcome was the difference in mean time-weighted DAS28-CRP between groups at 24 weeks. RESULTS: From July 2020 to November 2023, 83 consecutive patients with RA were included, with 78 initiating a new b/tsDMARD (TDM-based group: n = 38; control: n = 40). The mean time-weighted DAS28-CRP was 3.15 in both groups (TDM: SD, 0.99; control: SD, 1.01; 95% CI of difference: -0.46 to 0.47). There were no significant differences between the groups in flare rates, escape medication use, disease activity, or adverse events. Receiver operating characteristic analyses in the control group found no predictive value of adalimumab levels for response to TNFi or non-TNFi. CONCLUSIONS: Switching treatments based on adalimumab trough levels was not more effective than random switching in patients with RA who failed adalimumab treatment. Therefore, serum drug level measurements to guide therapy choices in this context is not recommended.
引用
- Wientjes MHM, Atiqi S, Wolbink GJ, et al. Adalimumab serum concentration to choose a subsequent biological DMARD in patients with rheumatoid arthritis (ADDORA-switch): results of a blinded randomised test-treatment trial. Ann Rheum Dis. 2025. PMID: 40318979. doi:10.1016/j.ard.2025.03.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。